DOPAMINE HYDROCHLORIDE Concentrate for solution for infusion (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Dopamine Hydrochloride 40mg/ml Concentrate for Solution for Infusion.
Qualitative and quantitative composition
Each ml contains 40 mg dopamine hydrochloride. Each 5 ml ampoule contains 200mg Dopamine hydrochloride Excipient(s) with known effect: Each 5mL ampoule contains 50 mg sodium metabisulfite. Each 5mL ampoule ...
Pharmaceutical form
Concentrate for solution for infusion. Clear, colourless or pale yellow solution.
Therapeutic indications
For the correction of haemodynamic imbalances in low-perfusion circulatory insufficiency associated with myocardial infarction, trauma, septicaemia, cardiac failure and open heart surgery.
Posology and method of administration
Posology Adults Use as large a vein as possible for infusion. The initial rate of infusion is 2 to 5 micrograms per kilogram bodyweight per minute and this may be increased gradually by increments of 5 ...
Contraindications
Dopamine should not be used in patients with – Hypersensitivity to dopamine or any of the excipients listed in section 6.1. Phaeochromocytoma or hyperthyroidism. Dopamine should not be used in the presence ...
Special warnings and precautions for use
Warnings Patients who have been treated with MAO inhibitors prior to dopamine should be given reduced doses; the starting dose should be one tenth (1/10<sup>th</sup>) of the usual dose. Excess administration ...
Interaction with other medicinal products and other forms of interaction
Anaesthetics The myocardium is sensitised by the effect of dopamine, cyclopropane or halogenated hydrocarbon anaesthetics, and these should be avoided. This interaction applies both to pressor activity ...
Fertility, pregnancy and lactation
Pregnancy Animal studies have shown no evidence of teratogenic effects with dopamine. However, the effect of dopamine on the human foetus is unknown. Therefore the drug should be used in pregnant women ...
Effects on ability to drive and use machines
Not applicable in view of the indications for use and the short half-life of the drug.
Undesirable effects
Adverse reactions to dopamine are related to its pharmacological action. The following adverse reactions are classified by system organ class and ranked under heading of frequency: Common (>1/100 to <1/10; ...
Overdose
Excessive elevation of blood pressure and vasoconstriction can occur due to the alpha adrenergic actions of dopamine, especially in patients with a history of occlusive vascular disease. If desired, this ...
Pharmacodynamic properties
Pharmacotherapeutic group: adrenergic and dopaminergic agents ATC code: C01CA04 Dopamine (3,4-dihydroxyphenylethylamine) is the third naturally occurring catecholamine and is a metabolic precursor of noradrenaline ...
Pharmacokinetic properties
Dopamine is inactive when taken orally and its vasoconstrictor properties preclude its administration by subcutaneous or intramuscular injection. Dopamine hydrochloride is administered by intravenous infusion ...
Preclinical safety data
No further relevant information other than that which is included in other sections of the Summary of Product Characteristics.
List of excipients
Sodium metabisulfite Water for injections
Incompatibilities
Iron salts, alkalis or oxidising agents. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
36 months. For single use only If only part of an ampoule is used, discard the remaining solution. Diluted solutions should be used immediately. Discard any remaining solution
Special precautions for storage
Do not store above 25°C. Keep the container in the outer carton in order to protect from light.
Nature and contents of container
5 ml clear glass one point-cut (OPC) ampoules, glass Type I Ph Eur. borosilicate glass ampoules packed in cardboard cartons to contain 10 5ml ampoules.
Special precautions for disposal and other handling
This solution must be diluted before use. Do not dilute with alkaline solution. Inspect the solution before use. Do not use the injection if it is darker than slightly yellow or discoloured in any other ...
Marketing authorization holder
Mercury Pharma International Ltd, 4045, Kingswood Road, City West Business Park, Co Dublin, Ireland
Marketing authorization number(s)
PL 02848/0130
Date of first authorization / renewal of the authorization
14 September 1989 / 19 March 2008
Date of revision of the text
17/09/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: